Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233063 | 0.84 | DGAT1 (0.55) | DGAT1ALDH1A1PTGS2HTTL3MBTL1 | |
| SCHEMBL5302124 | 0.83 | DGAT1 (0.71) | DGAT1MEN1KMT2ATDP1HPGD | |
| SCHEMBL18415349 | 0.81 | MEN1 (0.51) | DGAT1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL5300455 | 0.80 | DGAT1 (0.58) | DGAT1NPC1RAB9A | |
| SCHEMBL4788254 | 0.79 | DGAT1 (0.62) | DGAT1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4787021 | 0.79 | DGAT1 (0.65) | DGAT1MEN1KMT2A | |
| SCHEMBL5307790 | 0.78 | DGAT1 (0.61) | DGAT1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL4788552 | 0.77 | DGAT1 (0.67) | DGAT1KMT2A | |
| SCHEMBL4618813 | 0.77 | DGAT1 (0.67) | DGAT1ALDH1A1PTGS2HTTL3MBTL1 | |
| SCHEMBL5302841 | 0.77 | DGAT1 (0.56) | DGAT1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | DGAT1 4267/4885ALDH1A1 3457/4885PTGS2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.